Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
Background/Aims This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy. Methods T...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2019-07-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://www.kjim.org/upload/pdf/kjim-2017-036.pdf |
| _version_ | 1818607622844055552 |
|---|---|
| author | Kyoung Min Cho Bhumsuk Keam Hyerim Ha Miso Kim Jae-Woo Jung Woo-Jung Song Tae Min Kim Yoon Kyung Jeon Hye-Ryun Kang Dong-Wan Kim Chul Woo Kim Dae Seog Heo |
| author_facet | Kyoung Min Cho Bhumsuk Keam Hyerim Ha Miso Kim Jae-Woo Jung Woo-Jung Song Tae Min Kim Yoon Kyung Jeon Hye-Ryun Kang Dong-Wan Kim Chul Woo Kim Dae Seog Heo |
| author_sort | Kyoung Min Cho |
| collection | DOAJ |
| description | Background/Aims This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy. Methods The medical records of 326 patients diagnosed with DLBCL were re trospectively analyzed. Both doctor’s progress records and nursing records were reviewed. IRR was graded according to the National Cancer Institute Common Terminology Criteria. Results IRR was not associated with overall survival (OS) or progression-free survival (PFS) of DLBCL patients as compared to those who did not have IRR (OS: median 78.0 months vs. 69.0 months, p = 0.700; PFS: median 65.4 months vs. 64.0 months, p = 0.901). IRR grade did not affect OS or PFS. B symptoms was independently associated with IRR (hazard ratio [HR], 1.850; 95% confidence interval [CI], 1.041 to 3.290; p = 0.036). Further, bone marrow involvement was independently associated with re-IRR (HR, 4.904; 95% CI, 0.767 to 3.118; p = 0.029). Conclusions Our study shows that IRR of rituximab is not associated with OS or PFS of DLBCL patients who received R-CHOP. Furthermore, our study suggests a need for more careful observation for IRR in patients with B symptoms or bone marrow involvement. |
| first_indexed | 2024-12-16T14:29:41Z |
| format | Article |
| id | doaj.art-659fe788572946c5b82f6fe24fe23f66 |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-12-16T14:29:41Z |
| publishDate | 2019-07-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-659fe788572946c5b82f6fe24fe23f662022-12-21T22:28:16ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482019-07-0134488589310.3904/kjim.2017.036169955Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOPKyoung Min Cho0Bhumsuk Keam1Hyerim Ha2Miso Kim3Jae-Woo Jung4Woo-Jung Song5Tae Min Kim6Yoon Kyung Jeon7Hye-Ryun Kang8Dong-Wan Kim9Chul Woo Kim10Dae Seog Heo11 Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Department of Pathology, Seoul National University Hospital, Seoul, Korea Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Department of Pathology, Seoul National University Hospital, Seoul, Korea Department of Internal Medicine, Seoul National University Hospital, Seoul, KoreaBackground/Aims This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy. Methods The medical records of 326 patients diagnosed with DLBCL were re trospectively analyzed. Both doctor’s progress records and nursing records were reviewed. IRR was graded according to the National Cancer Institute Common Terminology Criteria. Results IRR was not associated with overall survival (OS) or progression-free survival (PFS) of DLBCL patients as compared to those who did not have IRR (OS: median 78.0 months vs. 69.0 months, p = 0.700; PFS: median 65.4 months vs. 64.0 months, p = 0.901). IRR grade did not affect OS or PFS. B symptoms was independently associated with IRR (hazard ratio [HR], 1.850; 95% confidence interval [CI], 1.041 to 3.290; p = 0.036). Further, bone marrow involvement was independently associated with re-IRR (HR, 4.904; 95% CI, 0.767 to 3.118; p = 0.029). Conclusions Our study shows that IRR of rituximab is not associated with OS or PFS of DLBCL patients who received R-CHOP. Furthermore, our study suggests a need for more careful observation for IRR in patients with B symptoms or bone marrow involvement.http://www.kjim.org/upload/pdf/kjim-2017-036.pdfinfusion-related reactionrituximablymphoma, large b-cell, diffuseprognosischaracteristics |
| spellingShingle | Kyoung Min Cho Bhumsuk Keam Hyerim Ha Miso Kim Jae-Woo Jung Woo-Jung Song Tae Min Kim Yoon Kyung Jeon Hye-Ryun Kang Dong-Wan Kim Chul Woo Kim Dae Seog Heo Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP The Korean Journal of Internal Medicine infusion-related reaction rituximab lymphoma, large b-cell, diffuse prognosis characteristics |
| title | Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP |
| title_full | Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP |
| title_fullStr | Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP |
| title_full_unstemmed | Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP |
| title_short | Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP |
| title_sort | clinical significance of rituximab infusion related reaction in diffuse large b cell lymphoma patients receiving r chop |
| topic | infusion-related reaction rituximab lymphoma, large b-cell, diffuse prognosis characteristics |
| url | http://www.kjim.org/upload/pdf/kjim-2017-036.pdf |
| work_keys_str_mv | AT kyoungmincho clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT bhumsukkeam clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT hyerimha clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT misokim clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT jaewoojung clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT woojungsong clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT taeminkim clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT yoonkyungjeon clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT hyeryunkang clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT dongwankim clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT chulwookim clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop AT daeseogheo clinicalsignificanceofrituximabinfusionrelatedreactionindiffuselargebcelllymphomapatientsreceivingrchop |